HC Wainwright Predicts Increased Earnings for Cytokinetics

Key Points

• HC Wainwright raised its FY2026 earnings estimate for Cytokinetics to a loss of $5.89 per share from a projected loss of $6.38, maintaining a Buy rating and a $140 price target.
• Cytokinetics posted a third-quarter loss of $1.37 per share, beating the $1.43 loss analysts expected. Revenue reached $47.56 million versus estimates of $41.88 million, rising sharply year over year.
• Analyst sentiment is broadly positive: MarketBeat reports a “Moderate Buy” consensus and an average price target of $106.67, with 19 Buy ratings among 21 analysts.

Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Analysts at HC Wainwright upped their FY2026 earnings estimates for shares of Cytokinetics in a research note issued on Thursday, November 5th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings of ($5.89) per share for the year, up from their previous forecast of ($6.38). HC Wainwright currently has a "Buy" rating and a $140.00 price target on the stock. The consensus estimate for Cytokinetics' current full-year earnings is ($5.86) per share. HC Wainwright also issued estimates for Cytokinetics' Q4 2026 earnings at ($1.37) EPS, FY2027 earnings at ($5.07) EPS and FY2028 earnings at ($1.84) EPS.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter, beating the consensus estimate of ($1.43) by $0.06. The firm had revenue of $47.56 million during the quarter, compared to analyst estimates of $41.88 million. Cytokinetics's revenue was up 2356.5% on a year-over-year basis. During the same quarter last year, the business earned ($2.55) earnings per share.

Other analysts have also issued research reports about the company. JPMorgan Chase & Co. increased their price objective on Cytokinetics from $97.00 to $103.00 and gave the company an "overweight" rating in a report on Thursday, August 13th. Truist Financial boosted their target price on Cytokinetics from $106.00 to $112.00 and gave the stock a "buy" rating in a research note on Monday, August 10th. William Blair began coverage on Cytokinetics in a research report on Friday, October 16th. They set an "outperform" rating on the stock. Morgan Stanley raised Cytokinetics from an "overweight" rating to a "buy" rating in a research report on Tuesday, September 1st. Finally, Needham & Company LLC raised their price target on Cytokinetics from $102.00 to $112.00 and gave the stock a "buy" rating in a report on Friday, August 7th. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $106.67.

Cytokinetics Stock Performance

NASDAQ CYTK opened at $53.69 on Monday. The firm's fifty day simple moving average is $65.68 and its two-hundred day simple moving average is $69.97. The firm has a market capitalization of $6.68 billion, a P/E ratio of -8.89 and a beta of 0.45. Cytokinetics has a 12-month low of $53.55 and a 12-month high of $88.31.

Insider Activity at Cytokinetics

In other news, CEO Robert Blum sold 97,926 shares of Cytokinetics stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $69.33, for a total transaction of $6,789,209.58. Following the completion of the sale, the chief executive officer directly owned 385,320 shares in the company, valued at approximately $26,714,235.60. The trade was a 20.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 10,000 shares of the business's stock in a transaction on Monday, August 31st. The shares were sold at an average price of $70.24, for a total transaction of $702,400.00. Following the sale, the executive vice president directly owned 58,555 shares in the company, valued at $4,112,903.20. This trade represents a 14.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 173,426 shares of company stock worth $11,934,640. 2.60% of the stock is owned by company insiders.

Institutional Trading of Cytokinetics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Pictet Asset Management Holding SA increased its holdings in shares of Cytokinetics by 18.4% in the third quarter. Pictet Asset Management Holding SA now owns 1,374,523 shares of the biopharmaceutical company's stock valued at $90,569,000 after purchasing an additional 214,060 shares during the period. Principal Financial Group Inc. raised its stake in shares of Cytokinetics by 11.9% in the first quarter. Principal Financial Group Inc. now owns 1,093,485 shares of the biopharmaceutical company's stock worth $72,072,000 after purchasing an additional 116,593 shares during the last quarter. Fisher Asset Management LLC raised its stake in shares of Cytokinetics by 10.1% in the third quarter. Fisher Asset Management LLC now owns 818,832 shares of the biopharmaceutical company's stock worth $53,969,000 after purchasing an additional 75,135 shares during the last quarter. ADAR1 Capital Management LLC lifted its holdings in shares of Cytokinetics by 17.1% during the first quarter. ADAR1 Capital Management LLC now owns 632,556 shares of the biopharmaceutical company's stock worth $41,692,000 after purchasing an additional 92,390 shares during the period. Finally, Candriam S.C.A. lifted its holdings in shares of Cytokinetics by 39.3% during the third quarter. Candriam S.C.A. now owns 617,386 shares of the biopharmaceutical company's stock worth $40,841,000 after purchasing an additional 174,320 shares during the period.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Cytokinetics reported a third-quarter loss of $1.37 per share, narrower than the $1.43-per-share consensus loss, and revenue of $47.56 million versus expectations of $41.88 million. Revenue rose sharply year over year, and the loss narrowed from $2.55 per share a year earlier. Earnings results
• Positive Sentiment: RBC Capital Markets sees MYQORZO potentially driving a revenue inflection starting in 2027, supporting the longer-term growth case. RBC Capital Markets view
• Positive Sentiment: Analyst sentiment remained supportive: Morgan Stanley initiated a Buy view, while Citigroup raised its target to $105 and Leerink Partners set a new $100 target with an Outperform rating. Morgan Stanley rating Citigroup rating
• Neutral Sentiment: Leerink’s $100 target was reduced from $103, a modest cut that tempers the otherwise positive analyst news, though the firm maintained its Outperform rating. Leerink Partners rating

Cytokinetics Company Profile

Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance.

The company's work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.

Founded in 1997, Cytokinetics is based in South San Francisco, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.